Cargando…

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

BACKGROUND: Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; including n...

Descripción completa

Detalles Bibliográficos
Autores principales: Ailani, Jessica, McAllister, Peter, Winner, Paul K., Chakhava, George, Krog Josiassen, Mette, Lindsten, Annika, Sperling, Bjørn, Ettrup, Anders, Cady, Roger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164335/
https://www.ncbi.nlm.nih.gov/pubmed/35659622
http://dx.doi.org/10.1186/s12883-022-02714-1